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Abstract
Potential benefits of statins in the treatment of chronic kidney disease beyond lipid-lowering
effects have been described. However, molecularmechanisms involved in renoprotective
actions of statins have not been fully elucidated.We questioned whether statins influence
development of diabetic nephropathy through reactive oxygen species, RhoA and Akt/
GSK3 pathway, known to be important in renal pathology. Diabetic mice (db/db) and their
control counterparts(db/+) were treatedwith atorvastatin (10 mg/Kg/day, p.o., for 2 weeks).
Diabetes-associated renal injurywas characterized by albuminuria (albumin:creatinine
ratio, db/+: 3.2 ± 0.6 vs. db/db: 12.5 ± 3.1*; *P<0.05), increased glomerular/mesangial sur-
face area, and kidney hypertrophy. Renal injurywas attenuated in atorvastatin-treated db/
db mice. IncreasedROS generation in the renal cortex of db/dbmice was also inhibited by
atorvastatin. ERK1/2 phosphorylation was increased in the renal cortex of db/dbmice.
Increased renal expression of Nox4 and proliferating cell nuclear antigen, observed in db/
db mice, were abrogated by statin treatment. Atorvastatin also upregulatedAkt/GSK3β
phosphorylation in the renal cortex of db/dbmice. Our findings suggest that atorvastatin
attenuates diabetes-associated renal injury by reducing ROS generation, RhoA activity and
normalizingAkt/GSK3β signaling pathways. The present study provides some new insights
into molecularmechanismswhereby statins may protect against renal injury in diabetes.
Introduction
Kidney disease is associated with end-stage renal disease and continues to be a major cause of
morbidity and mortality in patients with diabetes [1–3]. Several factors contribute to the pro-
gression of diabetic nephropathy, including hyperglycemia, hypertension, dyslipidemia, pro-
duction of inflammatory cytokines and oxidative stress, triggering hypertrophic, proliferative,
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inflammatory and apoptotic events [2–4]. Identifying targets to ameliorate these processes may
be renoprotective and thereby reduce the renal complications of diabetes.While many thera-
peutic approaches have been considered, there is growing interest in the potential beneficial
effect of statins.
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzymeA (HMG-CoA)
reductase, a major enzyme in cholesterol synthesis, thus decreasing endogenous cholesterol
formation [5]. Clinical benefits of cholesterol reduction have been established in primary and
secondary interventional studies using statins, demonstrating that treatment with these drugs
decreasesmorbidity and mortality related to coronary heart disease [6, 7]. In addition, statins
have recently emerged as novel renoprotective drugs in several models of kidney injury, includ-
ing diabetic nephropathy, and for this reason are being investigated in a number of clinical tri-
als [8–10].
The protective effects of statins in the cardiovascular and renal systems may occur indepen-
dently of their lipid-lowering effect, and are referred as pleiotropic effects. Inhibition of activity
of small GTPases [small hydrolase enzymes that can bind and hydrolyze guanosine triphos-
phate (GTP)] is one of the major pleiotropic actions of statins [11–13]. These small G proteins,
including Ras, Rho, Rab, and Ran, are monomeric proteins with a low molecularmass that
elicit various key intracellular signals. In particular, a series of recent investigations has revealed
a novel contribution of Rho and its effectormolecule, Rho-kinase, to renal disease via inhibi-
tion and/or activation of different signaling pathways, such as Akt and NADPH oxidase, lead-
ing to modulation of cell motility, apoptosis and proliferative responses. However, it remains
unclear whether RhoA contributes to renal hypertrophy in diabetic individuals [2, 14–17].
Considering that some of the beneficial effects of statins are mediated by antioxidant effects
and RhoA inhibition [16, 18], the aim of the present study was to determine whether atorva-
statin decreases RhoA activity, ROS signaling and associated renal damage in the leptin recep-
tor deficient db/db mouse, a rodent model of obesity and type 2 diabetes. In addition, we
questioned whether the Akt/GSK3β pathway, important in cell survival, is sensitive to effects of
atorvastatin.We tested the hypothesis that atorvastatin, through redox-sensitive and RhoA-
dependent mechanisms, attenuates diabetes-associatednephropathy. We also questioned
whether atorvastatin prevents renal hypertrophy by modulating the Akt/GSK3β pathway. We
previously reported that atorvastatin ameliorates vascular injury in db/dbmice. Here we extend
that study by investigating effects of atorvastatin on diabetic nephropathy. To respect the
principles of the 3Rs (Replacement, Reduction and Refinement) in research, we examinedmice
that we have previously characterized [19].
Material andMethods
Animals
The study was approved by the Animal Ethics Committee of Ottawa Hospital Research Insti-
tute—University of Ottawa. Experiments were conducted in accordance with the guidelines
from the National Institutes of Health Guide for the Care and Use of Laboratory Animals and
with Institutional guidelines. Leprdb/Lepr+ (db/+) and Leprdb/Leprdb (db/db) mice (B6.BKS
(D)-Leprdb/J) were purchased from Jackson Laboratories (Maine, USA). Male mice (8 weeks
of age) were treated with 10 mg/kg/day atorvastatin (Millipore Corporation, Billerica,MA,
USA), p.o. for 2. Atorvastatin was incorporated into the chow (2018 Teklad Global 18% Protein
Rodent Diet, Harlan Laboratories,Madison,WI), after previous assessment of daily food intake
(db/+: 0,063 g atorvastatin/Kg chow; db/db: 0,056 g atorvastatin/Kg chow). Mice were killed by
CO2 inhalation. Kidney samples used in this study were obtained frommice used in our previ-
ous study [19].
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Assessment of urinaryalbumin and creatinine
Spot urine samples were collected immediately before death. Urine albumin-to-creatinine ratio
was measured using a commercial kit (Albuwell and Creatinine companion kit; Exocell, Phila-
delphia, PA) as recommended by the Animal Models of Diabetic Complications Consortium
[20].
Renal hypertrophy and histopathologic analysis
Kidneys were removed and weighed. The kidney weight (g) was corrected by the length of the
tibia (mm). Kidneys were fixed in 4% paraformaldehyde (PFA) solution for 24 h, dehydrated,
embedded in paraffin and transversely sectioned (4 μm). Sectionswere stained with Masson
Trichrome for measurement of mesangial (MA) and glomerular (GA) areas. Sections were
visualizedwith a Zeiss AxioCamHRc (Zeiss Axio Imager; Zeiss, Oberkochen,Germany), and a
magnification of 100x. At least 20 glomeruli in each section (two sections per kidney) from five
mice/group were examined. Glomerular area was measured using Masson Trichrome-stained
kidney sections (ImageJ software, National Institute of Health).
Detection of renal NADPH oxidase activity by lucigenin
chemiluminescence
Activation of renal NADPH oxidase was assessed using the lucigenin-derived chemilumines-
cence assay [21].
Immunohistochemistry
Localization of PCNA and RhoA in kidneys was studied by immunohistochemistryusing pol-
yclonal antibodies against anti-proliferating cell nuclear antigen (PCNA) (Cell Signaling, Dan-
vers, Massachusetts, USA) and RhoA (Abcam, Cambridge,MA, USA). Four-μm thick sections
of ZBF-fixed, paraffin-embeddedkidneys on Superfrost Plus slides were deparaffinised in
xylene and rehydrated in graded alcohol baths. Immunohistostaining was performed according
to the manufacturer’s instructions (Vector Laboratories, Burlingame, CA, USA).
Immunoblotting
Total protein was extracted from the kidneys cortex. Briefly, frozen tissues were homogenized
in 50 mMTris-HCl (pH 7.4) lysis buffer (containing 1% Nonited P-40, 0.5% sodiumdeoxycho-
late, 150 mMNaCl, 1 mM EDTA, 0.1% sodium dodecyl sulfate (SDS), 2 mM sodium orthova-
nadate (Na3VO4), 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 μg/mL pepstatin A, 1 μg/
mL leupeptin and 1 μg/mL aprotinin). Total protein extracts were centrifuged at 10,000 rpm
for 10 min and the pellet was discarded. Proteins from homogenates of renal tissues (50 μg)
were separated by electrophoresis on a polyacrylamide gel (10%), and transferred onto a nitro-
cellulosemembrane. Nonspecific binding sites were blocked with 5% skimmilk or 1% bovine
serum albumin (BSA) in Tris-buffered saline solution with Tween for 1 hour at 24°C. Mem-
branes were then incubated with specific antibodies overnight at 4°C. Antibodies were as fol-
lows: anti-Nox4, anti-vascular cell adhesion molecule 1 (VCAM-1), anti-osteopontin (OPN),
anti-PCNA, anti-glycogen synthase kinase-3 beta (GSK-3β) (Ser9); anti-nuclear factor-kB
(NF-kB) subunit p65 (Ser536), anti-Akt (Ser473), anti-p38MAPK (Thr180/Tyr182), anti- SAPK/
JNKMAPK (Thr183/Tyr185) and anti-ERK1/2 (Thr202/Tyr204) (Cell Signaling, Danvers, Massa-
chusetts, USA), anti-β-actin (Sigma). After incubation with secondary antibodies, signals were
revealed by chemiluminescence, visualized by autoradiography and quantified densitometri-
cally. Values were corrected and normalized for β-actin expression [19, 22].
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Cytosol and membrane fractionation
RhoA activity was determined by measuring RhoA translocation from the cytosol to the mem-
brane. This is a well defined and accepted assay of RhoA activation [8, 23, 24]. Kidney cortex
was homogenized in 50 mM Tris-HCl, pH 7.4, lysis buffer containing 5 mmol/L EGTA, 2
mmol/L EDTA, 0.1 mmol/L PMSF, 0.2 mmol/L Na3VO4, 1 μmol/L pepstatin A, 1 μmol/L leu-
peptin, and 1 μmol/L aprotinin). Homogenates were centrifuged at 100,000 g for 1 hour at 4°C.
The supernatant (cytosolic fraction) was collected. The pellet, containing the particulate frac-
tion, was resuspended in lysis buffer containing 1% Triton X-100 and centrifuged at 10,000 g
for 10 min at 4°C. The resultant supernatant was collected (membrane-enriched fraction). Pro-
tein analysis was performed by western blotting as described above using anti-RhoA (1:500,
Santa Cruz). Antibody to β-actin (Sigma) was used as internal housekeeping control. Results
are expressed as the membrane to cytosol ratio of protein content in the cell fractions.
Data Analysis
Results are presented as mean ± SEM. Comparisons were performed by one-way ANOVA fol-
lowed by the Bonferroni test or the Newman–Keuls test, when appropriate. P<0.05 was con-
sidered statistically significant.
Results
Atorvastatin is renoprotective in db/dbmice
Db/dbmice exhibited renal hypertrophy and increased PCNA protein expression in tubular
epithelial and glomerularmesangial cells in the renal cortex when compared to db/+mice. Kid-
ney mass was reduced in treated db/db mice versus untreated mice. This was associated with
decreased PCNA overexpression (Fig 1A–1C).
Diabetic db/dbmice exhibited proteinuria compared to db/+ control mice. Treatment
reduced proteinuria in db/db mice (Fig 2A). These functional changes were associated with
glomerular structural changes in db/dbmice, evidenced by enhancedmesangial (MA) and glo-
merular (GA) surface areas compared to control db/+mice. These effects were attenuated in
the treated diabetic group (Fig 2B–2D).
Mechanismswhereby atorvastatin influences renal function in db/db
mice–role of RhoA activation
Statins have direct effects on the activity of small GTPases such as RhoA. RhoA activity was
assessed by evaluating cytosol-to-membrane translocation of RhoA. Increased RhoA protein
content was observed in membrane-enriched fractions of the renal cortex of db/dbmice com-
pared with control db/+mice. The higher membrane:cytosol RhoA expression ratio indicates
increased RhoA activity in the renal cortex of the db/dbmice. In db/dbmice treated with ator-
vastatin renal RhoA translocation was significantly reduced (Fig 3A). Immunohistochemical
analysis revealed that RhoA expression is increased in tubular epithelial cells, as well as in glo-
merularmesangial cells in renal cortex of db/dbmice, versus controls, an effect that is attenu-
ated by atorvastatin (Fig 3B).
Since oxidative stress triggers various pro-inflammatory, pro-fibrotic and proliferative sig-
naling pathways involved in cardiovascular and renal damage, we analyzed renal NADPH oxi-
dase activity by the lucigenin chemiluminescence assay. Fig 4A shows that diabetic db/dbmice
exhibited increased superoxide generation in the renal cortex compared to control db/+mice.
This was associated with an increased expression of Nox4 in the renal cortex (Fig 4B). Activa-
tion of NADPH oxidase and upregulation of Nox4 were attenuated in treated mice.
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Fig 1. Increased renalmass and PCNA protein content in db/dbmice are attenuatedby atorvastatin treatment.
Renal mass (A) expressed as kidney weight (g) and length of tibia (mm) ratio. PCNA expression (B) and localization (c)
determined in the kidney cortex by western blot and immunochemistry, respectively, of db/+ and db/dbmice treated
with atorvastatin (10mg/kg/day for 2 weeks) or control diet. Top panel, representative immunoblots of PCNA and β-
actin expression. Results are mean ± SEM of 3–6mice in each experimental group. *P< 0.05 vs. db/+ control diet,
**P<0.05 db/db atorvastatin diet vs. db/db control diet and db/+ atorvastatin diet.
doi:10.1371/journal.pone.0162731.g001
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Renal inflammation in diabetic mice is unaffected by atorvastatin
Renal cortex from diabeticmice exhibited increasedOPN protein expression and increased
phosphorylation of p65 NFkB subunit compared to kidneys from control db/+mice. Atorva-
statin did not influenceOPN expression or the magnitude of phosphorylation of p65 NFkB
(Fig 5A and 5B). In addition, no differences were observed for VCAM-1 expression between
the groups (Fig 5C).
Differential activation of renal JNK, p38MAPK and ERK1/2 in db/db
mice–effects of atorvastatin
Mitogen-activated protein kinases (MAPK) are redox-sensitive proteins. Since increased ROS
generation was detected in the renal cortex of db/dbmice, MAPK activation, inferred from
phosphorylation levels, was determined in kidneys of diabeticmice by western blot. No differ-
ences were observed in SAPK/JNKMAPK or p38 MAPK phosphorylation between the groups
(Fig 6A and 6B). ERK1/2 phosphorylation/activitywas increased in the renal cortex of diabetic
mice, and this was blunted by atorvastatin treatment (Fig 6C). Atorvastatin had no significant
effect on phosphorylation of SAPK/JNKMAPK or p38 MAPK.
Atorvastatin normalizes phosphorylationof Akt and GSK3β in renal
cortex of diabetic mice
Renal mass and expression of the proliferative marker PCNA were augmented in renal cortex
of diabeticmice. Therefore, the activity of proteins involved in hypertrophic gene program-
ming, specificallyAkt and GSK3β, was also investigated. Phosphorylation levels of Akt and
GSK3β were significantly reduced in renal cortex of db/dbmice compared with control db/
+ mice. Atorvastatin restored renal phosphorylation levels of these proteins in db/dbmice (Fig
7A and 7B).
Discussion
Obesity and diabetes are major co-morbidities associated with cardiovascular complications,
nephropathy and end stage-renal disease. Together with other elements of the metabolic syn-
drome, including hypertension, diabetes and obesity are interrelated and contribute to progres-
sion of renal disease.Multiple factors act in concert to initially cause renal vasodilation,
glomerular hyperfiltration, and albuminuria, leading to the development of glomerulopathy
[25–27]. Here we studied a model of diabetes and obesity in db/dbmice, focusing on renal
damage, and questioned whether statins ameliorate nephropathy, since our previous findings
demonstrated significant vasoprotection by statins in these mice.
Major findings in the present study demonstrate that atorvastatin reduces renal hypertro-
phy and dysfunction in diabetic obesemice. These processes are associated with reduced ROS
generation, downregulation of hypertrophic signaling pathways, decreased activation of redox-
sensitive ERK1/2, and restoration of Akt and GSK3β activity. Protective actions of atorvastatin
are not generalized phenomena, because renal inflammation in db/dbmice was unaffected by
statin treatment. Our data suggest that statins may have an important impact on diabetes-
Fig 2. Atorvastatin treatment reducesmesangial expansion in db/dbmice.Graphs depict albuminuria (A),
glomerular surface area (B), mesangial area, in blue (C) and representative images of a single glomerulus stained
with Masson Trichrome (D) from db/+ and db/dbmice treatedwith atorvastatin (10mg/kg/day for 2 weeks) or control
diet. Results are presented as mean ± SEM of 20 glomerular andmesangial areas in sections from 5 mice in each
group. *P< 0.05 vs. db/+ control diet, **P<0.05 vs. db/db atorvastatin diet vs. db/db control diet and db/+ atorvastatin
diet. (Black scale bar: 10 μm,magnification x100).
doi:10.1371/journal.pone.0162731.g002
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associated nephropathy. These effects are highly regulated and may be beneficial as adjuvant
therapy in the renal complications of diabetes.
Statins, HMG-CoA reductase inhibitors, exhibit actions beyond their cholesterol-lowering
properties, and seem to have direct vascular and renal protective effects, although exact mecha-
nisms still remain unclear [5, 28–31]. We previously reported that atorvastatin improves endo-
thelial function and ameliorates vascular inflammation through processes that reduce
oxidative stress. Statins also influence antioxidant systems [28] and through formation of iso-
prenoids, promote hydrophobic modifications of small GTPases, such as Rac1/2, which play a
crucial role in the activation of NADPH oxidases [28], and RhoA [30].
In the present study, atorvastatin reduced renal Nox4 protein expression and ROS genera-
tion and normalized RhoA activity in db/dbmice. In addition, statins decreased diabetes-asso-
ciated renal dysfunction (albuminuria) and prevented renal damage and cell proliferation, as
evidencedd by PCNA protein expression and immunolocalization. In particular, db/db kid-
neys exhibited increased proliferation of mesangial and tubular epithelial cells p and hypertro-
phy, in line with previous studies [32,33]. Our data are in agreement with these and other
studies showing that statins improve renal structure both in type 1 and type 2 experimental dia-
betes [8, 34–36] and also in patients with type 1 diabetes [37]. The effects of atorvastatin
observed in our study do not seem to be agent-specific as other statins, such as simvastatin,
Fig 3. Atorvastatin reducesRhoA translocation from cytosol to themembane in kidneys of diabetic
mice.RhoA translocation (A) and RhoA immunolocalization (B) from renal cortex obtained from db/+ and db/
db mice treatedwith atorvastatin (10mg/kg/day for 2 weeks) or control diet. Translocation of RhoA was
assessed by protein expression in themembrane and cytosolic fractions isolated from renal cortex
homogenates. Results are mean ± SEM of 3–6mice in each experimental group. *P< 0.05 vs. db/+ control
diet, **P<0.05 db/db atorvastatin diet vs. db/db control diet.
doi:10.1371/journal.pone.0162731.g003
Fig 4. Atorvastatin reduces oxidative stress andNox4 protein expression in kidney from db/dbmice.ROS status was assessed
by lucigenin-enhanced chemiluminescence (A) and Nox4 protein expression (B) by western blotting in renal cortex homogenates from
db/+ and db/dbmice treatedwith atorvastatin (10mg/kg/day for 2 weeks) or control diet. Results are mean ± SEM of 6–8mice in each
experimental group. *P< 0.05 vs. db/+ control diet, **P<0.05 db/db atorvastatin diet vs. db/db control diet.
doi:10.1371/journal.pone.0162731.g004
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pitavastatin and rosuvastatin have also been shown to have some renoprotective actions in
experimentalmodels of diabetes [8, 38].
Fig 5. Atorvastatindoes not change expressionof inflammatory markers in the renal cortex of db/dbmice.Phosphorylationof NF-κB
p65 (A) and the expression of OPN (B) and VCAM-1 (C) were evaluated in renal cortex isolated from db/+ and db/dbmice treatedwith
atorvastatin (10mg/kg/day for 2 weeks) or control diet. Top panels, representative immunoblots of NF-κB p65 [Ser536], OPN, VCAM-1 and β-
actin. Results are mean ± SEM of 6–8mice in each experimental group. *, P< 0.05 vs. db/+ control diet.
doi:10.1371/journal.pone.0162731.g005
AtorvastatinAttenuates Renal Damage in db/dbMice
PLOSONE | DOI:10.1371/ journal.pone.0162731 September 20, 2016 10 / 16
Rho GTPases play an important role in renal integrity and function [29, 39, 40]. Of impor-
tance, transgenic mice expressing doxycycline-inducible constitutively active or dominant-neg-
ative RhoA in podocytes revealed that RhoA, in basal conditions, maintains the integrity of the
glomerular filtration barrier, but increased RhoA activity promotes podocyte injury [39]. In
addition, mice subjected to nephrectomy present podocytedysfunction, which is attenuated by
RhoA signaling inhibition [40]. RhoA also is involved in renal integrity in diabeticmice; its
inhibitors attenuate diabetes-induced renal hypertrophy in different models of diabetes,
including db/db mice [8, 41], supporting a role for RhoA/Rho kinase in diabetes-associated
Fig 6. Increased renal ERK1/2 MAPKphosphorylation is abrogatedby atorvastatin in db/dbmice.Phosphorylation
levels of SAPK/JNKMAPK (A), p38MAPK (B), and ERK1/2MAPK (C) were evaluated in renal cortex isolated from db/+ and
db/dbmice treatedwith atorvastatin (10mg/kg/day for 2 weeks) or control diet. Top panels, representative immunoblots of
SAPK/JNKMAPK [Thr183/Tyr185], p38MAPK [Thr180/Tyr182], ERK1/2MAPK [Thr202/Tyr204] and β-actin. Results are
presentedas mean ± SEM of 6–8mice in each experimental group. *P< 0.05 vs. db/+ control diet, **P<0.05 db/db
atorvastatin diet vs. db/db control diet.
doi:10.1371/journal.pone.0162731.g006
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nephropathy. Of importance, inhibition of the small GTPase RhoA, by fasudil or statins,
reduces renal Nox4 protein expression in streptozotocin-induced type 1 diabetes [1] as well as
in db/dbmice [35]. RhoAmay be activated in the endoplasmic reticulum upstream of Nox4 in
isolated endothelial cells [42]. TGF-β activates RhoA/ROCKsignaling regulating Nox4 activity
in kidneymyofibroblasts [43]. These studies reinforce our findings suggesting that abnormali-
ties in renal structuremight be associated with altered RhoA signaling and Nox4-induced oxi-
dative stress. Moreover, we found that RhoA content was increased in glomerularmesangial
and tubular epithelial cells in db/dbmice. Although atorvastatin did not significantly influence
RhoA content, it reduced RhoA activity as evidenced by decreased cytosol-to-membrane trans-
location. Exact mechanisms whereby RhoA and Nox4 interact and how this impacts on podo-
cyte dysfunction and mesangial proliferation remain elusive and warrant further investigation.
Redox-sensitive proteins such as MAP kinases regulate many cellular functions including cell
growth, differentiation, proliferation, and apoptosis [41]. Stress-activated protein kinase
(SAPK)/JNKMAPK and p38MAPK are related mainly to stress or cell injury responses, while
ERK1/2 is associated with mitogenic and growth factor stimulation [41, 42]. Whereas no differ-
ences were found in renal SAPK/JNKMAPK or p38MAPK phosphorylation/activity in kid-
neys of db/dbmice, ERK1/2 activity was increased and may have contributed to diabetes-
associated renal hypertrophy.
Othermolecular processes underlying renal damage in diabetes include dysregulation of sig-
naling pathways that control cell survival and cellular protection. In particularAkt is critical
for podocyte survival and normal renal function [43]. An important downstream substrate of
Akt is GSK3β [44]. In our study, both Akt and GSK3β were significantly downregulated in db/
db mice and may reflect tissue damage and associated reduced cell survival. These findings are
in line with the hypertophic and injured phenotype observed in the diabetic group in our
study. Atorvastatin normalized activity of Akt and GSK3β, suggesting cellular protection,
Fig 7. ReducedAkt andGSK3β phosphorylation in the renal cortexof db/dbmice is restoredby atorvastatin.
Phosphorylation levels of Akt (A) and GSK3β (B) were evaluated in renal cortex isolated from db/+ and db/dbmice treated
with atorvastatin (10mg/kg/day for 2 weeks) or control diet. Top panels, representative immunoblots of Akt [Ser473], GSK3β
[Ser9] and β-actin. Results aremean ± SEM of 6–8mice in each experimental group. *P< 0.05 vs. db/+ control diet, **P<0.05
db/db atorvastatin diet vs. db/db control diet.
doi:10.1371/journal.pone.0162731.g007
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processes which may contribute to the overall renal protective actions of statin treatment in
diabetes. Exactly how atorvastatin normalizes these processes is unclear, but may relate, in
part, to reduced oxidative stress and decreasedRho kinase signaling. RhoA activation has been
shown to trigger apoptosis dependent on increased phosphatase and tensin homolog (PTEN)
activity, which inactivates the pro-survival protein Akt to suppress cell survival [45].
In conclusion, our data suggest that atorvastatin attenuates renal damage in diabeticmice
through ROS- and RhoA-dependent mechanisms. Moreover, Akt and GSK3β normalization
contribute to atorvastatin actions, processes that may be dependent on ERK1/2 activation.
While atorvastatin improved renal functional and structural alterations in diabetes, inflamma-
tory processes were not sensitive to statin treatment in our model. The present study advances
our understanding on some molecularmechanisms related to type 2 diabetes-associated renal
damage and identifies putative pathways modulated by statins. These findings have particular
clinical relevance because recent studies have demonstrated that atorvastatin is renoprotective
in patients with early diabetic nephropathy [37, 46]. The molecularmechanisms identified in
our study may explain, at least in part, clinical benefits of atorvastatin in human diabetic kidney
disease.
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